EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Prognostic value of platelet-to-lymphocyte ratio in bladder cancer: a systematic review and meta-analysis

Mengyuan Pan, Tianyi Tao, Jialing Peng, Yuliang Zhang, Dehui Kong, Kang Chen, Hantao Wu, Bo Yang, Hua Gong

Clinical and Translational Oncology · 22.07.2026

DOI: 10.1007/s12094-026-04515-1 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical and Translational Oncology, online erschienen am 22.07.2026. Verfasst von Mengyuan Pan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Henan Medical University, Xinxiang, 453003, China. Die Arbeit nennt 59 Literaturangaben. Gefördert von: The Outstanding Leaders Training Program of Shanghai Pudong New Area Health Commission, Natural Major Foundation of Shanghai University of Medicine & Health Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognosis of bladder cancer (BC) necessitates reliable biomarkers. The platelet-to-lymphocyte ratio (PLR), a composite indicator of systemic inflammation and immune status, has shown prognostic potential in multiple studies, but evidence remains inconsistent and incomplete regarding key survival outcomes.

Methods

In accordance with the PRISMA guidelines, a systematic literature search was conducted through June 2026 across PubMed, Embase, Web of Science, and the Cochrane Library. Pooled hazard ratios (HRs) with their 95% confidence intervals (CIs) were calculated using a random-effects model to evaluate the association between elevated pretreatment PLR and overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), and cancer-specific survival (CSS). Subgroup and sensitivity analyses were conducted, along with an evaluation of potential publication bias. All statistical procedures were executed using STATA version 15.0 and Review Manager version 5.4.

Results

This meta-analysis included 26 studies involving a total of 5,807 patients. Elevated pretreatment PLR was significantly associated with shorter OS (HR = 1.56, 95% CI: 1.27–1.93), RFS (HR = 1.95, 95% CI: 1.47–2.59), PFS (HR = 1.85, 95% CI: 1.36–2.53), and CSS (HR = 1.56, 95% CI: 1.27–1.92). Sensitivity analysis confirmed the robustness of the results for OS, RFS, and PFS, while CSS results showed lower stability. Subgroup analysis revealed heterogeneity in the prognostic value of PLR, primarily driven by variations in PLR cut-off values, tumor type, patient age, geographic region, and treatment regimen. OS results showed signs of publication bias (Egger's test, P = 0.000), in contrast to RFS, PFS, and CSS.

Conclusion

Elevated pretreatment PLR was significantly associated with adverse survival outcomes in patients with BC. As an accessible and cost-effective inflammatory-immune biomarker, PLR may serve as a useful adjunctive tool for risk stratification, although its independent clinical utility requires validation in prospective settings. Future prospective studies are warranted to establish standardized cut-off values and further clarify its role in prognostic assessment and personalized treatment decision-making.

Schlagwörter

Stichwörter der Autor:innen

BiomarkerBladder cancerMeta-analysisPlatelet to lymphocyte ratioPrognostic value of survival

Autor:innen und Institutionen

  • Graduate School, Henan Medical University, Xinxiang, 453003, China.
  • Department of Urology, Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai, 201318, China.
  • Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
  • Graduate School, University of Shanghai for Science and Technology, Shanghai, 200093, China.
  • School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China.
  • Experimental Cellular Therapy Group, University of California San Francisco, San Francisco, 94103, USA.

Förderung

  • The Outstanding Leaders Training Program of Shanghai Pudong New Area Health Commission
  • Natural Major Foundation of Shanghai University of Medicine & Health Sciences

Zitieren

APA

Pan, M., Tao, T., Peng, J., Zhang, Y., Kong, D., Chen, K., Wu, H., Yang, B., & Gong, H. (2026). Prognostic value of platelet-to-lymphocyte ratio in bladder cancer: a systematic review and meta-analysis. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04515-1

Vancouver

Pan M, Tao T, Peng J, Zhang Y, Kong D, Chen K, et al. Prognostic value of platelet-to-lymphocyte ratio in bladder cancer: a systematic review and meta-analysis. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04515-1

BibTeX
@article{Pan2026,
  author = {Pan, Mengyuan and Tao, Tianyi and Peng, Jialing and Zhang, Yuliang and Kong, Dehui and Chen, Kang and Wu, Hantao and Yang, Bo and Gong, Hua},
  title = {Prognostic value of platelet-to-lymphocyte ratio in bladder cancer: a systematic review and meta-analysis},
  journal = {Clinical and Translational Oncology},
  year = {2026},
  doi = {10.1007/s12094-026-04515-1}
}
Kostenlos starten →